PHOENIX-GC:腹腔与静脉紫杉醇联合S-1对比顺铂联合S-1治疗胃癌腹膜转移的III期试验
PHOENIX-GC是一项随机III期试验,纳入183例胃癌腹膜转移患者,按2:1随机接受腹腔+静脉紫杉醇联合S-1(IP)或S-1联合顺铂(SP)。
要点
- IP组3年OS率21.9%,SP组6.0%;两方案耐受性均良好。
核心结论
- 本试验未显示腹腔紫杉醇联合全身化疗对总生存期的统计学优效性。
- 探索性分析提示腹腔紫杉醇对胃癌腹膜转移患者可能存在临床获益。
研究设计与样本
- 随机III期试验,纳入183例胃癌腹膜转移且未接受或仅短期(<2个月)化疗的患者。
- 按2:1随机分配至IP组或SP组,按中心、既往化疗和腹膜转移程度分层。
- 主要终点为总生存期;次要终点为缓解率、3年总生存率和安全性。
- 疗效分析纳入164例符合方案患者。
主要发现
- IP组3年总生存率为21.9%(95%CI 14.9%-29.9%),SP组为6.0%(95%CI 1.6%-14.9%)。
- 两方案均耐受良好。
关键数值与推荐
- IP方案:腹腔紫杉醇20 mg/m2和静脉紫杉醇50 mg/m2于第1、8天,联合S-1 80 mg/m2/日第1-14天,3周为一周期。
- SP方案:S-1 80 mg/m2/日第1-21天,联合顺铂60 mg/m2第8天,5周为一周期。
临床怎么用
- 标准全身化疗仍为胃癌腹膜转移的参考方案之一。
- 腹腔紫杉醇联合全身化疗可作为探索性选择,尤其对伴有腹水的患者需进一步验证。
局限性
- 主要终点未达统计学显著性。
- IP组腹水患者显著多于SP组,基线不平衡可能影响结果。
- 疗效分析仅纳入164例符合方案患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis. The primary end point was overall survival. Secondary end points were response rate, 3-year overall survival rate, and safety. Results We enrolled 183 patients and performed efficacy analyses in 164 eligible patients. Baseline characteristics were balanced between the arms, except that patients in the IP arm had significantly more ascites. The median survival times for the IP and SP arms were 17.7 and 15.2 months, respectively (hazard ratio, 0.72; 95% CI, 0.49 to 1.04; stratified log-rank P = .080). In the sensitivity analysis adjusted for baseline ascites, the hazard ratio was 0.59 (95% CI, 0.39 to 0.87; P = .008). The 3-year overall survival rate was 21.9% (95% CI, 14.9% to 29.9%) in the IP arm and 6.0% (95% CI, 1.6% to 14.9%) in the SP arm. Both regimens were well tolerated. Conclusion This trial failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
引用
- Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018. PMID: 29746229. doi:10.1200/JCO.2018.77.8613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。